>> News


Apogenix develops protein therapeutics that could transform the treatment of life-threatening diseases by targeting critical pathways involved in the growth, migration, and apoptosis of diseased cells.

The company’s lead drug candidate APG101 is currently being evaluated in patients with glioblastoma (GB) – a disease with a tremendous need for new and effective therapies. A randomized controlled phase II trial in recurrent GB has shown that APG101 prolongs overall survival and improves quality of life, while exhibiting an excellent safety profile. Apogenix is also developing a companion diagnostic to identify patients who may respond best to treatment with APG101. APG101’s unique mode of action supports its significant potential for the treatment of other malignant diseases, such as myelodysplastic syndromes (MDS) as well as solid tumors beyond GB.

Please click here to watch a report by Deutsche Welle (Germany's international broadcaster) for a description of glioblastoma and APG101's mechanism of action.

Apogenix was founded as a spin-out of the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Since its inception in fall 2005, Apogenix has raised more than 50 million euros from its investors. In addition, the company was awarded public grants totaling 8.5 million euros, of which almost 5 million euros were granted as part of the so-called Leading-Edge Cluster Competition initiated by the German Federal Ministry of Education and Research (BMBF). Apogenix is based in Heidelberg, Germany, and currently has 29 employees.